Kymriah Alternatives Compared
| Kymriah (tisagenlecleucel) | Epkinly (epcoritamab) | Rituximab |
|
|---|
| Kymriah (tisagenlecleucel) | Epkinly (epcoritamab) | Rituximab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma. Kymriah may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma. Epkinly may also be used for purposes not listed in this medication guide. |
Prescription only
Rituximab (brand name Rituxan) is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia... View more |
Related suggestions Diffuse Large B-Cell Lymphoma
Popular comparisons
|
|||||||
| More about Kymriah (tisagenlecleucel) | More about Epkinly (epcoritamab) | More about Rituximab | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Rituximab has an average rating of 7.6 out of 10 from a total of 176 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Kymriah side effects |
View all Epkinly side effects |
View all Rituximab side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Epkinly prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
|
N/A |
N/A |
Riabni, Rituxan, Ruxience, Truxima | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
403.2 hours |
528 hours |
59.8 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 265 drugs are known to interact with Kymriah:
|
A total of 290 drugs are known to interact with Epkinly:
|
A total of 198 drugs are known to interact with Rituximab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
May 19, 2023 |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.